Vor Biopharma Inc. — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Vor is a clinical-stage cell and genome engineering company developing engineered hematopoietic stem cell and CAR-T candidates for blood cancers. It has no approved products and has generated no product revenue.
Financial performance and position
- Revenue and margins: No revenue in the periods presented; profitability and margins are not meaningful. The company expects no product sales revenue in the near future, if ever.
- Operating expenses: Q3 research and development expense was $16.9 million (up $4.0 million year over year) and general and administrative expense was $7.2 million (up $1.5 million). Nine-month expenses were $47.5 million for R&D and $21.2 million for G&A, up $12.7 million and $5.3 million, respectively.
- Loss: Q3 net loss was $23.8 million, versus $18.6 million in Q3 2021; nine-month net loss was $68.2 million, versus $50.6 million. Nine-month basic and diluted loss per share was $1.81, versus $1.62.
- Cash flow: Nine-month operating cash use was $66.8 million, compared with $51.6 million in 2021. Investing activities provided $2.9 million, chiefly reflecting maturities of securities, while financing provided $4.9 million, primarily from ATM share sales and option exercises.
- Liquidity: Cash, cash equivalents and marketable securities totaled $136.1 million at September 30, 2022, down from $207.5 million at year-end 2021. Current assets were $142.7 million and current liabilities $11.1 million. Management expected available funds to cover operating expenses and capital expenditures into Q1 2024; the financial statement note separately says funds should suffice for at least one year after issuance.
- Debt and leases: No debt outstanding. Operating lease liabilities totaled $40.3 million, including $3.8 million current. Lease amendments and another lease increased contractual obligations by $31.5 million during the first nine months; $1.4 million was due within 12 months.
Changes and notable items
- Higher R&D spending reflected increased personnel and stock compensation, laboratory and cGMP manufacturing expansion, and clinical and manufacturing costs for the ongoing VOR33 trial. G&A growth reflected personnel costs and headquarters expansion.
- Property and equipment, net, rose to $13.0 million from $6.9 million, including new manufacturing equipment. Operating lease right-of-use assets increased to $45.4 million from $15.7 million.
- Marketable securities had $1.2 million of unrealized losses, attributed to rising interest rates; the company reported no credit losses. Interest income rose to $0.5 million for the nine-month period from $0.1 million.
- The company sold 856,030 shares under its ATM facility in the first nine months, raising $4.3 million net; $120.5 million remained available at quarter-end. Dilution is a potential consequence of future equity fundraising.
Outlook, risks and contingencies
- Management anticipated initial clinical data from the VOR33 VBP101 Phase 1/2a trial in Q4 2022, with further engraftment and hematologic-protection updates in 2023. The filing notes enrollment delays partly related to COVID-19 and site readiness.
- Vor planned to submit an IND for VCAR33 ALLO in the first half of 2023. It no longer expected VCAR33 AUTO trial data in 2022; timing depended on the NMDP investigators. The company planned to await initial VOR33 and VCAR33 ALLO data before an IND submission for the combined Treatment System.
- Management expected significant ongoing losses and rising R&D costs, and stated that additional capital would be required. It cautioned that runway estimates rely on assumptions and that insufficient financing could force delays or cuts to programs or threaten continued operations.
- Key risks include unvalidated eHSC technology, clinical and regulatory uncertainty, trial enrollment and safety outcomes, reliance on third-party manufacturing and licensed intellectual property, competition, and possible COVID-19 or macroeconomic disruption. The filing reported no material change to previously disclosed risk factors and no material legal proceedings.
Investor verification points
- Track VBP101 enrollment, initial data and subsequent engraftment/protection updates against the stated timelines.
- Confirm actual cash burn, cash runway and financing needs; reconcile the Q1 2024 MD&A runway estimate with the note’s “at least one year after issuance” statement.
- Monitor ATM usage, remaining capacity, share-count growth and potential dilution.
- Assess lease-related commitments and capital spending for the expanded laboratory and manufacturing facilities.
- Verify VCAR33 ALLO IND timing and any updated VCAR33 AUTO data schedule.